337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study

Federico Nichetti, Antonio Marra, Carlo Alberto Giorgi, Giovanni Randon, Simone Scagnoli, Claudia De Angelis, Chiara Molinelli, Emanuela Ferraro, Dario Trapani, Andrea Milani, Elisa Agostinetto, Ottavia Bernocchi, Giovanni Catania, Carmen G. Rea, Debora Basile, Lorenzo Gerratana, M. Cinausero, Claudio VernieriAnnals 2020 · DOI

BibTeX
@article{nichetti2020p,
  author = {Federico Nichetti and Antonio Marra and Carlo Alberto Giorgi and Giovanni Randon and Simone Scagnoli and Claudia De Angelis and Chiara Molinelli and Emanuela Ferraro and Dario Trapani and Andrea Milani and Elisa Agostinetto and Ottavia Bernocchi and Giovanni Catania and Carmen G. Rea and Debora Basile and Lorenzo Gerratana and M. Cinausero and Claudio Vernieri},
  title = {{337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study}},
  journal = {Annals},
  year = {2020},
  doi = {10.1016/j.annonc.2020.08.439},
}

Loading related content...

Figure